Acutus Medical (AFIB) amendment: Director holds 3,281 shares and options

Rhea-AI Filing Summary

Acutus Medical, Inc. amendment to a Schedule 13G/A reports updated beneficial ownership disclosures by Advent Life Sciences LLP, Advent Life Sciences Fund I LP and Dr. Shahzad Malik.

The filing states Advent Life Sciences LLP and Advent Life Sciences Fund I LP each hold 0 shares. Dr. Shahzad Malik holds 3,281 restricted shares of common stock and options to purchase 19,476 shares, representing 0.07608% of the class. The reporting persons disclaim beneficial ownership except to the extent of any pecuniary interest. Signatures are dated 02/13/2026.

Insights

Corporate Governance Analyst

Minor insider holdings and option disclosure; routine amended Schedule 13G/A.

The amendment lists updated ownership: 3,281 restricted shares and options for 19,476 shares held by Dr. Shahzad Malik, with Advent Life Sciences entities holding 0 shares. The filing reiterates the standard disclaimer that reporting persons disclaim beneficial ownership except for any pecuniary interest.

These holdings equal 0.07608% of the class; timing and exercise conditions for the options are not detailed in the excerpt. Subsequent filings would show any option exercises or transfers.

Securities Compliance Specialist

Amendment formalizes previous joint filing and updates signature information.

The schedule references an agreement regarding joint filing dated February 11, 2022 and provides signed certifications dated 02/13/2026. The disclosure reflects ownership thresholds under 5% and class percentages consistent with Schedule 13G/A reporting.

This filing appears administrative in nature; cash‑flow treatment and any subsequent transactions are not stated in the provided excerpt.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

Acutus Medical, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

005111109

(CUSIP Number)

07/09/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 005111109

1

Names of Reporting Persons

Advent Life Sciences LLP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: Each Reporting Person disclaims beneficial ownership of the shares of Common Stock except to the extent of any pecuniary interest therein.

SCHEDULE 13G

CUSIP No. 005111109

1

Names of Reporting Persons

Advent Life Sciences Fund I LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: Each Reporting Person disclaims beneficial ownership of the shares of Common Stock except to the extent of any pecuniary interest therein.

SCHEDULE 13G

CUSIP No. 005111109

1

Names of Reporting Persons

Shahzad Malik

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 3,281.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 3,281.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

22,757.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.07608 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: Dr. Malik, a general partner of each of the funds named herein and who previously was a director of the Company, holds 3,281 restricted shares of Common Stock and options to purchase 19,476 shares of Common Stock. Each Reporting Person disclaims beneficial ownership of the shares of Common Stock except to the extent of any pecuniary interest therein.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Acutus Medical, Inc.
(b)	Address of issuer's principal executive offices: 2210 Faraday Ave., Suite 100, Carlsbad, CALIFORNIA 92008
Item 2.
(a)	Name of person filing: Advent Life Sciences LLP, Advent Life Sciences Fund I LP and Dr. Shahzad Malik.
(b)	Address or principal business office or, if none, residence: 27 Fitzroy Square, London, United Kingdom W1T 6ES
(c)	Citizenship: Advent Life Sciences LLP is a limited liability partnership organized under the laws of the United Kingdom. Advent Life Sciences Fund I LP is a limited partnership organized under the laws of the United Kingdom. Dr. Malik is a citizen of the United Kingdom.
(d)	Title of class of securities: Common Stock, par value $0.001 per share
(e)	CUSIP No.: 005111109
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: Advent Life Sciences LLP and Advent Life Sciences Fund I LP hold 0 shares. Dr. Malik, a general partner of each of the funds named herein and who previously was a director of the Company, holds 3,281 restricted shares of Common Stock and options to purchase 19,476 shares of Common Stock. Each Reporting Person disclaims beneficial ownership of the shares of Common Stock except to the extent of any pecuniary interest therein.
(b)	Percent of class: Advent Life Sciences LLP and Advent Life Sciences Fund I LP 0%. Dr. Malik 0.07608%.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Advent Life Sciences LLP and Advent Life Sciences Fund I LP 0%. Dr. Malik 0.01097%.
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: Advent Life Sciences LLP and Advent Life Sciences Fund I LP 0%. Dr. Malik 0.07608%.
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.	Certifications:
	Not Applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Advent Life Sciences LLP

Signature:	/s/ Shahzad Malik
Name/Title:	General Partner of Advent Life Sciences LLP
Date:	02/13/2026

Advent Life Sciences Fund I LP

Signature:	/s/ Shahzad Malik
Name/Title:	General Partner of Advent Life Sciences LLP acting in its capacity as Manager of Advent Life Sciences Fund I LP
Date:	02/13/2026

Shahzad Malik

Signature:	/s/ Shahzad Malik
Name/Title:	Shahzad Malik
Date:	02/13/2026

Comments accompanying signature: Please see notes re: reporting information and in signature information

Exhibit Information

Agreement Regarding the Joint Filing of Schedule 13G dated February 11, 2022 (as filed by the Reporting Persons on Schedule 13G on February 14, 2022).

FAQ

What ownership does Acutus Medical (AFIB) show for Dr. Shahzad Malik?

Dr. Shahzad Malik holds 3,281 restricted shares and options to purchase 19,476 shares, representing 0.07608% of the class as disclosed in the amendment.

Do Advent Life Sciences LLP or Fund I own shares in Acutus Medical (AFIB)?

No. The amendment states Advent Life Sciences LLP and Advent Life Sciences Fund I LP each hold 0 shares of the company’s common stock in this filing.

Does the filing state who receives proceeds if options are exercised?

The excerpt does not specify proceeds recipients for option exercises; the filing only lists options to purchase 19,476 shares held by Dr. Malik without cash‑flow details.

When was the Schedule 13G/A amendment signed?

Signatures on the amendment are dated 02/13/2026, and the document references an earlier joint filing agreement dated February 11, 2022.

Does this Schedule 13G/A indicate ownership above 5% for Acutus Medical (AFIB)?

No. The filing is categorized as Ownership of 5 Percent or Less of a Class and shows reported percentages at or below 0.07608% for the named reporting persons.